Celldex Therapeutics Announces Fireside Chat Presentation at the H.C. Wainwright Global Life Sciences Conference

Celldex Therapeutics (Nasdaq:CLDX) announced its participation in the H.C.

Rhea-AI Summary

Celldex Therapeutics (Nasdaq:CLDX) announced its participation in the H.C. Wainwright Global Life Sciences Conference, where a prerecorded fireside chat will be accessible to attendees starting March 9, 2021, at 7:00 a.m. ET. The presentation will be available via webcast on the company's website for fourteen days post-event. Celldex is focused on developing monoclonal and bispecific antibodies aimed at serious diseases, enhancing immune responses, and addressing areas with limited treatment options.

Positive

• Participation in the H.C. Wainwright Global Life Sciences Conference may enhance visibility and engagement with investors.
• Showcases the company's commitment to development in innovative antibody therapies for serious diseases.

Negative

• None.

Argus Session date unavailable

+4.01% session move Open Argus

Details

News Market Reaction – CLDX

The recorded move for CLDX in the trading session of this news was +4.01%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HAMPTON, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the Company’s participation in a fireside chat at the H.C. Wainwright Global Life Sciences Conference. The presentation for the virtual conference was prerecorded and will be accessible to conference attendees starting on Tuesday, March 9^th 2021 at 7:00 a.m. ET.

A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for fourteen days following the event.

About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly effect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
Celldex Therapeutics, Inc.
(781) 433-3161
scavanaugh@celldex.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Celldex's presentation at the H.C. Wainwright Global Life Sciences Conference?

The presentation will be accessible starting March 9, 2021, at 7:00 a.m. ET.

How can I access the Celldex conference presentation?

The presentation can be accessed via webcast on the 'Events & Presentations' page of the Celldex website.

How long will the Celldex presentation be available for viewing?

The replay of the presentation will be available for fourteen days following the event.

What does Celldex Therapeutics focus on?

Celldex is dedicated to developing monoclonal and bispecific antibodies for severe diseases with inadequate treatments.